- Home
- SOAR vs EDSA Comparison
SOAR vs EDSA Comparison
Compare SOAR & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- EDSA
- Stock Information
- Founded
- SOAR 2021
- EDSA 2015
- Country
- SOAR United States
- EDSA Canada
- Employees
- SOAR N/A
- EDSA N/A
- Industry
- SOAR Blank Checks
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- SOAR Finance
- EDSA Health Care
- Exchange
- SOAR Nasdaq
- EDSA Nasdaq
- Market Cap
- SOAR 15.7M
- EDSA 18.6M
- IPO Year
- SOAR N/A
- EDSA N/A
- Fundamental
- Price
- SOAR $1.81
- EDSA $2.07
- Analyst Decision
- SOAR
- EDSA Strong Buy
- Analyst Count
- SOAR 0
- EDSA 2
- Target Price
- SOAR N/A
- EDSA $13.00
- AVG Volume (30 Days)
- SOAR 2.5M
- EDSA 869.1K
- Earning Date
- SOAR 11-17-2025
- EDSA 12-12-2025
- Dividend Yield
- SOAR N/A
- EDSA N/A
- EPS Growth
- SOAR N/A
- EDSA N/A
- EPS
- SOAR N/A
- EDSA N/A
- Revenue
- SOAR $96,397,000.00
- EDSA N/A
- Revenue This Year
- SOAR N/A
- EDSA N/A
- Revenue Next Year
- SOAR N/A
- EDSA N/A
- P/E Ratio
- SOAR N/A
- EDSA N/A
- Revenue Growth
- SOAR 309.80
- EDSA N/A
- 52 Week Low
- SOAR $1.14
- EDSA $1.55
- 52 Week High
- SOAR $19.06
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- SOAR 42.95
- EDSA 36.14
- Support Level
- SOAR $1.75
- EDSA $1.90
- Resistance Level
- SOAR $2.28
- EDSA $2.94
- Average True Range (ATR)
- SOAR 0.50
- EDSA 0.20
- MACD
- SOAR -0.14
- EDSA -0.05
- Stochastic Oscillator
- SOAR 2.21
- EDSA 16.31
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.